Literature DB >> 2053596

The intratracheal administration of endotoxin and cytokines. I. Characterization of LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1-, and TNF-induced inflammatory infiltrate.

T R Ulich1, L R Watson, S M Yin, K Z Guo, P Wang, H Thang, J del Castillo.   

Abstract

Endotoxin (LPS), one of the major proinflammatory constituents of the cell walls of gram-negative bacteria, induces alveolar macrophages to express interleukin-1 (IL-1) and tumor necrosis factor (TNF) messenger RNA (mRNA), peaking at 1 hour in vitro. Intratracheal injection of LPS induces IL-1 and TNF mRNA expression in vivo in whole-lung RNA preparations. Interleukin-1 mRNA is not constitutively detected. In the case of TNF, however, a constitutively-expressed hybridization band is noted at 1.6 kb, whereas the LPS-induced hybridization band is noted at approximately 1.95 kb. Intratracheal injection of LPS induces an intra-alveolar inflammatory reaction composed of a neutrophilic exudate, peaking at 6 to 12 hours, a monocytic exudate peaking at 24 hours, and a lymphocytic exudate peaking at 48 hours, as quantitated by bronchoalveolar lavage. Intratracheal injection of IL-1 recapitulates the kinetics and relative magnitudes of the acute neutrophilic and chronic monocytic and lymphocytic inflammatory sequence. Intratracheal injection of TNF also induces an acute intraalveolar neutrophilic exudate, but TNF is much less potent of an inflammatory stimulus than IL-1. The effects of recombinant IL-1 and TNF are not due to LPS contamination, as shown by abrogation of the cytokines' inflammatory activity by boiling. In conclusion, LPS induces IL-1 and TNF mRNA expression in vitro in alveolar macrophages and in vivo in pulmonary tissue, and intratracheal injection of IL-1 and TNF recapitulates the LPS-induced pulmonary inflammatory sequence, strongly supporting the hypothesis that these cytokines play an important in vivo role in the pathogenesis of gram-negative bacterial pneumonia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2053596      PMCID: PMC1886409     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

1.  Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon.

Authors:  B B Aggarwal; T E Eessalu; P E Hass
Journal:  Nature       Date:  1985 Dec 19-1986 Jan 1       Impact factor: 49.962

2.  Cytokine- and calcium ionophore A23187-mediated arachidonic acid metabolism in neutrophils.

Authors:  T R Ulich; K Busser; K J Longmuir
Journal:  Cytokine       Date:  1990-07       Impact factor: 3.861

3.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

4.  Shock and tissue injury induced by recombinant human cachectin.

Authors:  K J Tracey; B Beutler; S F Lowry; J Merryweather; S Wolpe; I W Milsark; R J Hariri; T J Fahey; A Zentella; J D Albert
Journal:  Science       Date:  1986-10-24       Impact factor: 47.728

5.  In vivo inflammatory activity of epidermal cell-derived thymocyte activating factor and recombinant interleukin 1 in the mouse.

Authors:  R D Granstein; R Margolis; S B Mizel; D N Sauder
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

6.  Characterization of the pulmonary inflammatory response to an anaerobic bacterial challenge.

Authors:  S Nelson; B E Laughon; W R Summer; M A Eckhaus; J G Bartlett; G J Jakab
Journal:  Am Rev Respir Dis       Date:  1986-02

Review 7.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

8.  Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators.

Authors:  D Caput; B Beutler; K Hartog; R Thayer; S Brown-Shimer; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

9.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

Authors:  B Beutler; N Krochin; I W Milsark; C Luedke; A Cerami
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

10.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Authors:  C A Dinarello; J G Cannon; S M Wolff; H A Bernheim; B Beutler; A Cerami; I S Figari; M A Palladino; J V O'Connor
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  73 in total

1.  The pulmonary inflammatory response to experimental fecal peritonitis: relative roles of tumor necrosis factor-alpha and endotoxin.

Authors:  M A Mercer-Jones; M Heinzelmann; J C Peyton; D J Wickel; M Cook; W G Cheadle
Journal:  Inflammation       Date:  1997-08       Impact factor: 4.092

2.  Map kinase phosphatase 5 protects against sepsis-induced acute lung injury.

Authors:  Feng Qian; Jing Deng; Benjamin N Gantner; Richard A Flavell; Chen Dong; John W Christman; Richard D Ye
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

3.  Atopic asthmatic patients have reduced airway inflammatory cell recruitment after inhaled endotoxin challenge compared with healthy volunteers.

Authors:  Michelle L Hernandez; Margaret Herbst; John C Lay; Neil E Alexis; Willie June Brickey; Jenny P Y Ting; Haibo Zhou; David B Peden
Journal:  J Allergy Clin Immunol       Date:  2012-07-04       Impact factor: 10.793

4.  Low-level laser therapy (LLLT) acts as cAMP-elevating agent in acute respiratory distress syndrome.

Authors:  Flávia Mafra de Lima; Leonardo M Moreira; A B Villaverde; Regiane Albertini; Hugo C Castro-Faria-Neto; Flávio Aimbire
Journal:  Lasers Med Sci       Date:  2010-12-24       Impact factor: 3.161

5.  Toll-like receptor 4-dependent early elicited tumor necrosis factor alpha expression is critical for innate host defense against Bordetella bronchiseptica.

Authors:  Paul B Mann; Kelly D Elder; Mary J Kennett; Eric T Harvill
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Inflammatory bronchopulmonary response of preterm infants with microbial colonisation of the airways at birth.

Authors:  P Groneck; B Goetze-Speer; C P Speer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-01       Impact factor: 5.747

7.  Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis.

Authors:  Viviane Balloy; Michel Huerre; Jean-Paul Latgé; Michel Chignard
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

8.  High-Intensity Exercise Prevents Disturbances in Lung Inflammatory Cytokines and Antioxidant Defenses Induced by Lipopolysaccharide.

Authors:  Gisele Henrique Cardoso; Débora Melissa Petry; Jéssica Jorge Probst; Luiz Felipe de Souza; Gabriella Ganguilhet; Franciane Bobinski; Adair R S Santos; Daniel Fernandes Martins; Kelly Cattelan Bonorino; Alcir Luiz Dafre; Deborah de C Hizume Kunzler
Journal:  Inflammation       Date:  2018-12       Impact factor: 4.092

9.  Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue.

Authors:  Mark A Wortinger; Joseph W Foley; Patrick Larocque; Derrick R Witcher; Michael Lahn; Joseph A Jakubowski; Andrew Glasebrook; Ho Yeong Song
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

10.  CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury.

Authors:  Franco R D'Alessio; Kenji Tsushima; Neil R Aggarwal; Erin E West; Matthew H Willett; Martin F Britos; Matthew R Pipeling; Roy G Brower; Rubin M Tuder; John F McDyer; Landon S King
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.